Literature DB >> 2150817

In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.

R N Jones1, M E Erwin, M S Barrett.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150817     DOI: 10.1007/bf01967390

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  7 in total

1.  The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method.

Authors:  R N Jones; A L Barry
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

2.  The effect of charcoal on MICs for Legionella.

Authors:  J Barker; I D Farrell
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

3.  Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin.

Authors:  P B Fernandes; N Ramer; R A Rode; L Freiberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

4.  Antimicrobial activity and interaction of pefloxacin and its principal metabolites. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

5.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

6.  Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media.

Authors:  N Bornstein; C Roudier; J Fleurette
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

Review 7.  A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy.

Authors:  R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Jan-Feb       Impact factor: 2.803

  7 in total
  6 in total

1.  Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.

Authors:  D M Johnson; M E Erwin; M S Barrett; B B Gooding; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.

Authors:  S L Pendland; S J Martin; C Chen; P C Schreckenberger; L H Danziger
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

3.  In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; F Higa; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

4.  In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.

Authors:  S J Martin; S L Pendland; C Chen; P Schreckenberger; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 5.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

6.  Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.

Authors:  Khaled Abduljalil; Martina Kinzig; Jürgen Bulitta; Stefan Horkovics-Kovats; Fritz Sörgel; Michael Rodamer; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.